首页> 外文OA文献 >Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

【2h】

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

机译：恩替卡韦与阿德福韦治疗失代偿期肝硬化患者慢性乙型肝炎的成本效益从第三方美国付款人的角度来看

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tsai N; Jeffers L; Cragin L; Sorensen S; Su W; Rosenblatt L; Tang H; Hebden T; Juday T;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective [J] . Naoky Tsai, Lennox Jeffers, Lael Cragin, ClinicoEconomics and Outcomes Research . 2012,第10期

机译：从美国第三方付款方的观点来看，恩替卡韦和阿德福韦在失代偿性肝硬化患者中治疗慢性乙型肝炎的成本效益
2. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis [J] . PengH., LiuJ., YangM., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2014,第2期

机译：拉米夫定联合阿德福韦酯与恩替卡韦单药联合治疗乙型肝炎相关代偿性肝硬化的疗效：荟萃分析
3. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis [J] . PengH., LiuJ., YangM., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2014,第2期

机译：拉米夫定结合Adefovir Dipivoxil与孕产病患者对乙型肝炎相关解偿性肝硬化患者的疗效：META分析
4. Mathematical modeling based on lamivudine switching to adefovir dipivoxil and to entecavir anti-hepatitis B infection treatment [C] . IEEE 5th International Bio-Inspired Computing: Theories and Applications . 2010

机译：基于拉米夫定转为阿德福韦酯和恩替卡韦抗乙型肝炎感染治疗的数学模型
5. Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. [D] . Vutien, Philip. 2016

机译：慢性丙型肝炎的治疗率存在种族差异：在美国以人群为基础的队列研究，共73665名患者。
6. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective [O] . Naoky Tsai, Lennox Jeffers, Lael Cragin, 2012

机译：从美国第三方付款方的观点来看恩替卡韦和阿德福韦在失代偿性肝硬化患者中治疗慢性乙型肝炎的成本效益
7. PIN27 USING DECISION SIMULATION MODEL TO EVALUATE THE COST EFFECTIVENESS OF ENTECAVIR COMPARED TO ADEFOVIR THERAPY IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS:ANALYSES FROM A US PAYER PERSPECTIVE [O] . Yuan Y, Iloeje U, Parry D, 2007

机译：PIN27决策模拟模型用于评估拉维夫定难治性乙型肝炎（CHB）病人中与阿德福韦治疗相比的Entecavir的成本效益：来自美国付款人的分析

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

著录项

引文网络

相似文献

相关主题

期刊订阅